Author
Listed:
- Carl A. Machutta
(GlaxoSmithKline)
- Christopher S. Kollmann
(GlaxoSmithKline
Present address: Forma Therapeutics Inc., 500 Arsenal Street, Watertown, Massachussetts 02472, USA)
- Kenneth E. Lind
(GlaxoSmithKline)
- Xiaopeng Bai
(GlaxoSmithKline)
- Pan F. Chan
(GlaxoSmithKline)
- Jianzhong Huang
(GlaxoSmithKline)
- Lluis Ballell
(GlaxoSmithKline)
- Svetlana Belyanskaya
(GlaxoSmithKline)
- Gurdyal S. Besra
(University of Birmingham, School of Biosciences)
- David Barros-Aguirre
(GlaxoSmithKline)
- Robert H. Bates
(GlaxoSmithKline)
- Paolo A. Centrella
(GlaxoSmithKline
Present address: X-Chem Pharmaceuticals, 100 Beaver Street, Waltham, Massachussetts 02453, USA)
- Sandy S. Chang
(GlaxoSmithKline)
- Jing Chai
(GlaxoSmithKline)
- Anthony E. Choudhry
(GlaxoSmithKline)
- Aaron Coffin
(GlaxoSmithKline
Present address: UT Southwestern Medical Center, 5323 Harry Hines BLVD., Dallas, Texas 75390, USA)
- Christopher P. Davie
(GlaxoSmithKline)
- Hongfeng Deng
(GlaxoSmithKline)
- Jianghe Deng
(GlaxoSmithKline)
- Yun Ding
(GlaxoSmithKline)
- Jason W. Dodson
(GlaxoSmithKline)
- David T. Fosbenner
(GlaxoSmithKline)
- Enoch N. Gao
(GlaxoSmithKline)
- Taylor L. Graham
(GlaxoSmithKline)
- Todd L. Graybill
(GlaxoSmithKline)
- Karen Ingraham
(GlaxoSmithKline)
- Walter P. Johnson
(GlaxoSmithKline)
- Bryan W. King
(GlaxoSmithKline)
- Christopher R. Kwiatkowski
(GlaxoSmithKline)
- Joël Lelièvre
(GlaxoSmithKline)
- Yue Li
(GlaxoSmithKline)
- Xiaorong Liu
(GlaxoSmithKline)
- Quinn Lu
(GlaxoSmithKline)
- Ruth Lehr
(GlaxoSmithKline)
- Alfonso Mendoza-Losana
(GlaxoSmithKline)
- John Martin
(GlaxoSmithKline)
- Lynn McCloskey
(GlaxoSmithKline)
- Patti McCormick
(GlaxoSmithKline)
- Heather P. O’Keefe
(GlaxoSmithKline)
- Thomas O’Keeffe
(GlaxoSmithKline)
- Christina Pao
(GlaxoSmithKline
Present address: Otsuka Pharmaceuticals, 508 Carnegie Center, Princeton, New Jersey 08540, USA)
- Christopher B. Phelps
(GlaxoSmithKline)
- Hongwei Qi
(GlaxoSmithKline)
- Keith Rafferty
(GlaxoSmithKline)
- Genaro S. Scavello
(GlaxoSmithKline)
- Matt S. Steiginga
(GlaxoSmithKline)
- Flora S. Sundersingh
(GlaxoSmithKline)
- Sharon M. Sweitzer
(GlaxoSmithKline)
- Lawrence M. Szewczuk
(GlaxoSmithKline
Present address: Janssen Pharmaceuticals, Molecular and Cellular Pharmacology, 1400 McKean RD, Spring House, Pennsylvania 19477, USA)
- Amy Taylor
(GlaxoSmithKline)
- May Fern Toh
(GlaxoSmithKline
Present address: Alkermes Pharmaceuticals, 852 Winter Street, Waltham, Massachussetts 02451, USA)
- Juan Wang
(GlaxoSmithKline)
- Minghui Wang
(GlaxoSmithKline)
- Devan J. Wilkins
(GlaxoSmithKline
Present address: Northeastern Reproductive Medicine, 105 W View Road, Colchester, Vermont 05446, USA)
- Bing Xia
(GlaxoSmithKline)
- Gang Yao
(GlaxoSmithKline)
- Jean Zhang
(GlaxoSmithKline)
- Jingye Zhou
(GlaxoSmithKline
Present address: Eli Lilly and Company, 222 Hubin Rd, Lu Wan Qu, Shanghai Shi 200021, China)
- Christine P. Donahue
(GlaxoSmithKline)
- Jeffrey A. Messer
(GlaxoSmithKline)
- David Holmes
(GlaxoSmithKline)
- Christopher C. Arico-Muendel
(GlaxoSmithKline)
- Andrew J. Pope
(GlaxoSmithKline)
- Jeffrey W. Gross
(GlaxoSmithKline)
- Ghotas Evindar
(GlaxoSmithKline)
Abstract
The identification and prioritization of chemically tractable therapeutic targets is a significant challenge in the discovery of new medicines. We have developed a novel method that rapidly screens multiple proteins in parallel using DNA-encoded library technology (ELT). Initial efforts were focused on the efficient discovery of antibacterial leads against 119 targets from Acinetobacter baumannii and Staphylococcus aureus. The success of this effort led to the hypothesis that the relative number of ELT binders alone could be used to assess the ligandability of large sets of proteins. This concept was further explored by screening 42 targets from Mycobacterium tuberculosis. Active chemical series for six targets from our initial effort as well as three chemotypes for DHFR from M. tuberculosis are reported. The findings demonstrate that parallel ELT selections can be used to assess ligandability and highlight opportunities for successful lead and tool discovery.
Suggested Citation
Carl A. Machutta & Christopher S. Kollmann & Kenneth E. Lind & Xiaopeng Bai & Pan F. Chan & Jianzhong Huang & Lluis Ballell & Svetlana Belyanskaya & Gurdyal S. Besra & David Barros-Aguirre & Robert H., 2017.
"Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening,"
Nature Communications, Nature, vol. 8(1), pages 1-11, December.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms16081
DOI: 10.1038/ncomms16081
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms16081. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.